The Department of Veterans Affairs (VA) is issuing a presolicitation notice for the procurement of Acamprosate Calcium 333mg extended-release tablets. This requirement is specifically for the VA CMOP facility in Tucson, Arizona, under solicitation number 36C77024Q0392, with a response deadline set for September 17, 2024. The procurement is categorized as a small business set-aside, aligning with NAICS code 325412, which pertains to pharmaceutical manufacturing. Interested vendors must submit their package via email, including documents such as the signed SF1449 cover page, an Excel price schedule, and a valid state wholesale distributor license. Additionally, vendors quoting non-domestic products must provide a Buy American Act certificate. Failure to include required documentation will result in non-compliance. Responses should focus on the specified requirement, with all offers due by the established deadline. The contract aims to ensure a timely delivery of the pharmaceutical within 10 days after receipt of order. The document emphasizes compliance with the Drug Supply Chain Security Act and underscores the importance of registration on SAM.gov for all vendors interested in participating.

The document details a Request for Quote (RFQ) issued by the Tucson Compounded Medication Operations Program (CMOP) with the RFQ number 36C77024Q0392. Vendors interested in providing ACAMPROSATE CA 333MG EC TAB must submit their bids by the closing date of September 17, 2024, at 4:00 PM CST, with delivery anticipated within ten days of the award. Required submissions include a signed SF1449 form, an excel quote spreadsheet, a valid State Wholesale Distributor License, and a Buy American Act certificate for non-domestic quotes. Vendors must ensure that pharmaceutical expiration dates are at least one year from delivery; any exceptions should be noted in the vendor comments. The specific quantity requested is 180 units, with additional information concerning the manufacturer, packaging, and pricing to be included in the submissions. The RFQ emphasizes a small business set-aside and compliance with the Buy American Act, indicating a preference for domestically sourced products. This RFQ reflects the federal government's ongoing efforts to procure essential pharmaceutical supplies while supporting small businesses.

The solicitation 36C77024Q0392 invites offers for the procurement of Acamprosate 333mg EC tablets primarily aimed at supporting the Department of Veterans Affairs (VA) in its pharmaceutical needs. The offer deadline is September 17, 2024, with a delivery schedule requiring items to be shipped within 10 days after receipt of the purchase order. Suppliers are expected to provide a comprehensive submission package that includes pricing schedules, valid state licenses, and other certifications related to drug origin and compliance with regulations. Key requirements include adherence to labeling standards, ensuring shipments are adequately documented, and compliance with the Drug Supply Chain Security Act. Contractors must maintain strict product quality, including specific provisions for drug recalls and proper drug labeling, supported by barcoding. The contract terms adhere to the Federal Acquisition Regulation (FAR) and specific VA clauses, detailing payment processes, inspection rights, and termination conditions. The document emphasizes the government's commitment to small businesses, providing set aside opportunities for various categories such as women-owned and service-disabled veteran-owned businesses. This procurement showcases the VA’s effort to ensure high standards for pharmaceuticals supplied to its facilities, aligning with broader objectives of efficiency and compliance in government contracting.